Download Image
    
Share
  
Post
Baloxavir for COVID-19
1 study with 20 patients
Hospital Icon Control
Hospital Icon Baloxavir Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Baloxavir studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -200% Viral clearance -600% RCTs -200% Late -200% Favorsbaloxavir Favorscontrol
Oct 25
2020
 Lou et al., European Journal of Pharmaceutical Sciences, doi:10.1016/j.ejps.2020.105631 Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial
20% improved recovery (p=1) and 600% worse viral clearance (p=0.21). Small late stage RCT with 10 favipiravir, 10 baloxavir marboxil, and 10 control patients in China, showing no significant differences. The single-dose influenza regimen produced plasma levels far below the SARS-CoV-2 EC50.